These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 22179417)

  • 21. The impact of dietary calcium intake and vitamin D status on the effects of zoledronate.
    Bourke S; Bolland MJ; Grey A; Horne AM; Wattie DJ; Wong S; Gamble GD; Reid IR
    Osteoporos Int; 2013 Jan; 24(1):349-54. PubMed ID: 22893357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months.
    Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Callon KE; Gamble GD; Reid IR
    J Bone Miner Res; 2008 Aug; 23(8):1304-8. PubMed ID: 18627266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Zoledronic acid for preventing fractures. HORIZON trial (Health Outcomes and Reduced Incidence with Zoledronic acid ONce yearly)].
    Ringe JD; Nitschmann S
    Internist (Berl); 2008 Apr; 49(4):502-4. PubMed ID: 18305914
    [No Abstract]   [Full Text] [Related]  

  • 24. Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate.
    Al-Bogami MM; Alkhorayef MA; Bystrom J; Akanle OA; Al-Adhoubi NK; Jawad AS; Mageed RA
    Saudi Med J; 2015 Nov; 36(11):1305-11. PubMed ID: 26593163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Annual zoledronic acid for osteoporosis.
    BMJ Group
    Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.
    Boonen S; Black DM; Colón-Emeric CS; Eastell R; Magaziner JS; Eriksen EF; Mesenbrink P; Haentjens P; Lyles KW
    J Am Geriatr Soc; 2010 Feb; 58(2):292-9. PubMed ID: 20070415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis.
    Huang J; Meixner L; Fernandez S; McCutchan JA
    AIDS; 2009 Jan; 23(1):51-7. PubMed ID: 19050386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis.
    Brown JJ; Zacharin MR
    J Pediatr Endocrinol Metab; 2009 Jan; 22(1):55-63. PubMed ID: 19344075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New bone density conservation agents for osteoporosis under research and development: Zoledronate].
    Wada S; Fukawa T; Kamiya S
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():421-5. PubMed ID: 18161143
    [No Abstract]   [Full Text] [Related]  

  • 30. A once-yearly IV bisphosphonate for osteoporosis.
    Obstet Gynecol; 2008 May; 111(5):1208-9. PubMed ID: 18448761
    [No Abstract]   [Full Text] [Related]  

  • 31. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study.
    Wessel JH; Dodson TB; Zavras AI
    J Oral Maxillofac Surg; 2008 Apr; 66(4):625-31. PubMed ID: 18355585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of intravenous bisphosphonates in osteoporosis.
    Civitelli R; Napoli N; Armamento-Villareal R
    Curr Osteoporos Rep; 2007 Mar; 5(1):8-13. PubMed ID: 17320022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Respiratory complications associated with IV zoledronic acid infusion in the treatment of postmenopausal osteoporosis.
    Taggart H; Cheng J; Archbold P
    Osteoporos Int; 2010 Sep; 21(9):1621-2. PubMed ID: 19813042
    [No Abstract]   [Full Text] [Related]  

  • 34. Successful treatment of transient osteoporosis with intravenous zoledronate: a case report.
    Maslin D; Karanth M; Bhagat S; Guirguis R
    Int J Rheum Dis; 2014 Sep; 17(7):816-7. PubMed ID: 24673857
    [No Abstract]   [Full Text] [Related]  

  • 35. Avascular necrosis of the proximal carpal row of the wrist. A possible complication of bisphosphonate administration.
    Didden K; De Smet L; Vandenberghe L; Sciot R; Degreef I
    Chir Main; 2012 Dec; 31(6):355-7. PubMed ID: 23177907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) associated with a once-yearly IV infusion of zoledronic acid (Reclast) 5 mg: two cases and review of the literature.
    Katz J; Ordoveza PA
    Quintessence Int; 2014 Sep; 45(8):685-90. PubMed ID: 25019116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Factors associated with acute febrile reaction in elderly patients receiving intravenous zoledronic acid for osteoporosis].
    Deng HO; Li DF; Zhang WJ; Zhi XM; Xu L; Wu W
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec; 31(12):2076-8. PubMed ID: 22200716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spontaneously recovered severe thrombocytopaenia following zoledronic acid infusion for osteoporosis.
    Kulkarni P; Cushman T; Donthireddy V; Rao S
    BMJ Case Rep; 2016 Feb; 2016():. PubMed ID: 26843222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
    Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zoledronic acid: a review of its use in the treatment of osteoporosis.
    Deeks ED; Perry CM
    Drugs Aging; 2008; 25(11):963-86. PubMed ID: 18947264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.